Trial Profile
A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin/epinephrine (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Matrix Pharmaceutical
- 17 Sep 2005 New trial record.